TME Pharma (formerly known as NOXXON Pharma) is a clinical-stage biopharmaceutical company that focuses on the development of proprietary therapeutics for the treatment of cancer. It offers Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidates, NOX-A12 and NOX-E36, which are under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia.